VWD Guidelines: Second Anniversary Update
Speaker(s): Lena Volland and Nikole Scappe
NHF's Wednesday Webinars are a free education series open to providers and community members. Register to attend and learn…
Recruitment is now open for Own Your Path- a program for young adult males with hemophilia who are currently in the transition years between 18-29. We know that maintaining adherence to a prophy regimen can have short and long -term health benefits…
Recruitment is now open for Own Your Path- a program for young adult males with hemophilia who are currently in the transition years between 18-29. We know that maintaining adherence to a prophy regimen can have short and long -term health benefits…
It’s time to lace up your running shoes! NHF is participating in the 2023 United Airlines NYC Half Marathon on Sunday, March 19, 2023. Team NHF will run 13 miles, from Brooklyn to Manhattan, raising funds and awareness for the inheritable…
Dr. von Drygalski's research focuses on better understanding the mechanisms operating the anti-fibrinolytic system and how this process works in patients with hemophilia and specifically with joint bleeding. Accelerated fibrinolysis and clot…
FOR IMMEDIATE RELEASE
Ilana Ostrin
Senior Director of Public Relations and Communications
iostrin@hemophilia.org
212-328-3769
NHF Assumes Leadership of the American Plasma Users Coalition
The organization’s…
Pfizer recently announced positive top-line results from the phase 3 BENEGENE-2 clinical study, which is currently evaluating the investigational gene therapy fidanacogene elaparvovec for the treatment of adult males with moderately severe to severe…
This session will provide educational knowledge on various concerns of aging that are affecting currently those aging with hemophilia and may affect future cohorts of those aging with hemophilia.
Presenters include Dr. Tam Perry, Dr.…
FOR IMMEDIATE RELEASE
Ilana Ostrin
Senior Director of Public Relations and Communications
iostrin@hemophilia.org
212-328-3769
NHF Announces 2023 Winter/Spring Wednesday Webinar Schedule
The free series will continue in the…
Takeda recently announced favorable results from a phase 3 study of TAK-755, the company’s investigational enzyme replacement therapy for an ultra-rare blood disorder known as congenital thrombotic thrombocytopenic purpura (cTTP).
cTTP is a…